Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India

Shots:

• Rockwell to receive up front, milestones and royalties on sales of Triferic. Sun Pharma to get an exclusive right to develop & commercialize Triferic, following its approval in India
•  Sun Pharma will be responsible for all clinical, regulatory and commercialization activities of Triferic in India. The collaboration allows Sun Pharma to expand its portfolio in its core therapy areas
• Rockwell’s Triferic is a US FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment

Click here ­to­ read full press release/ article | Ref: Sun Pharma | Image: Behance